GlassScriptPhysician profile
Stuart Paul Davis
NPI 1811043540
$115,268.29
in general payments reported to CMS, 2019-2025
32 companies · $7,719 in 2025
The $7,719 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $19K · 2021: $9,186 · 2022: $8,413 · 2023: $21K · 2024: $6,692 · 2025: $7,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $7,271 · Travel and Lodging: $2,421 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,350.00 |
| Food and Beverage | $7,271.42 |
| Travel and Lodging | $2,421.38 |
| Education | $188.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $39,656.20 | 2019-2024 | Jornay Pm |
| Abbvie INC. | $39,105.69 | 2021-2025 | Vraylar |
| Allergan, INC. | $13,999.26 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12,811.18 | 2019-2025 | Trintellix |
| Neuronetics, INC. | $1,957.55 | 2019-2025 | Neurostar Tms Therapy System |
| Supernus Pharmaceuticals, INC. | $1,150.81 | 2019-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $1,139.44 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $740.96 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $683.04 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Alkermes, INC. | $681.41 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $573.89 | 2022-2025 | Auvelity |
| Bausch Health US, LLC | $458.46 | 2019-2025 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $396.83 | 2022-2025 | Dyanavel Xr, Onyda Xr |
| Corium, LLC | $366.38 | 2021-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $280.58 | 2020-2025 | Caplyta |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $235.56 | 2020-2023 | Adzenys Xr-Odt |
| Avanir Pharmaceuticals, INC. | $235.22 | 2019-2022 | |
| Noven Therapeutics, LLC | $175.86 | 2023-2025 | Xelstrym, Secuado |
| Sunovion Pharmaceuticals INC. | $104.60 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $91.43 | 2022-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $90.97 | 2024-2025 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $90.40 | 2023-2025 | Quviviq, Quviviq |
| Eisai INC. | $49.48 | 2021 | |
| Adlon Therapeutics L.P. | $35.45 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $27.53 | 2021-2022 | |
| Shire North American Group INC | $25.18 | 2019 | |
| Aytu Biopharma, INC. | $21.99 | 2024 | |
| Azurity Pharmaceuticals, INC. | $19.48 | 2024 | |
| Vertical Pharmaceuticals, LLC | $18.43 | 2025 | Relexxii |
| Merck Sharp & Dohme LLC | $16.04 | 2023 | Belsomra |
| Almatica Pharma LLC | $15.00 | 2024 | Loreev Xr |
| Alfasigma USA, INC. | $13.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.